Market Overview:
The global polymyositis treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of polymyositis, increasing awareness about the disease, and technological advancements in the field of polymyositis treatment. However, high cost associated with treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global polymyositis treatment market is segmented into immunosuppressant, alkylating agent, immunoglobulin therapy, monoclonal antibodies therapy and corticosteroids therapy. Immunosuppressants are further sub-segmented into calcineurin inhibitors (CNIs), glucocorticoids and mammalian target of rapamycin inhibitors (mTORIs). Alkylating agents are further sub-segmented into nitrogen mustards and platinum analogs. Immunoglobulin therapies are further sub-segmented into intravenous immunoglobulins (IVIg) and subcutaneous immunoglobulins (SCIg). Monoclonal antibodies therapies are further sub-segmented into anti–interleukin 6 receptor monoclonal antibody (tocilizumab) and others.
Product Definition:
Polymyositis Treatment is a medical intervention that is used to improve the symptoms of polymyositis. Polymyositis is a rare autoimmune disorder that affects the muscles. The main goal of treatment for polymyositis is to improve muscle strength and function. Treatment may include medications, physical therapy, and lifestyle changes.
Immunosuppressant:
Immunosuppressant drugs are used to reduce the immune response to a transplanted organ or tissue. They do this by decreasing or suppressing the production of cytokines, which are substances that signal cells to move towards a foreign body and attack it. The most common side effects of immunosuppressants include skin rash, high blood pressure, swelling in legs & feet, low blood cell count (anemia), diabetes mellitus type 2 and loss of appetite.
Alkylating Agent:
Alkylating agents are a group of chemicals that react with proteins to cause damage to the body. Alkylating agents include nitrogen mustards, non-nitrogen mustards, alkyl phosphates, and methyl phosphates. Alkylation can lead to the formation of cross-links between amino acids in muscle tissue which results in muscle weakness or even permanent damage if not removed from the body quickly enough.
Application Insights:
The others application segment held the largest share of more than 60.0% in 2017. The other applications include research settings and home care settings among others. Polymyositis is a rare disease which affects mostly the elderly people, thus making it difficult to treat at home as compared to hospital-based conditions where nurses, doctors and technicians are available around the clock for round-the-clock treatment monitoring and support services. Thus, majority of patients with polymyositis are admitted in hospitals for better management of symptoms due to less availability of skilled personnel at homes or clinics resulting in higher market penetration rate among other applications across various regions globally.
Polymyositis treatment involves multiple drugs administered through a combination therapy that includes immunosuppressant drugs along with steroids or nonsteroidal antiinflammatory drug (NSAID) painkillers such as aspirin or ibuprofen depending upon severity of pain caused by inflammation associated polyneuropathy (Babinski sign).
Regional Analysis:
North America dominated the global polymyositis treatment market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing R&D activities for new drug development are some of the major factors responsible for North America’s dominance. In addition, rising awareness about various treatments available for different autoimmune diseases is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Moreover, growing medical tourism industry due to affordable treatment costs will further boost revenue generation in this region during the forecast period.
Growth Factors:
- Increasing incidence of polymyositis
- Growing awareness about the disease among people
- Rising demand for better and effective treatment options for polymyositis
- Availability of government funding for research on polymyositis treatment 5. Technological advancements in the field of polymyositis treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Polymyositis Treatment Market Research Report
By Type
Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids
By Application
Hospitals, Clinic, Others
By Companies
Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, Genentech, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
159
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Polymyositis Treatment Market Report Segments:
The global Polymyositis Treatment market is segmented on the basis of:
Types
Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hospira, Inc.
- Antares Pharma, Inc.
- Medexus Pharma, Inc.
- Fresenius SE & Co. KGaA
- Mylan N.V.
- Alcami Corporation
- Teva Pharmaceuticals
- Novartis AG
- Genentech, Inc.
Highlights of The Polymyositis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunosuppressant
- Alkylating Agent
- Immunoglobulin
- Monoclonal Antibodies
- Corticosteroids
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Polymyositis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Polymyositis treatment typically includes medications to help improve the symptoms, physical therapy to help improve muscle function, and a supportive care plan. Treatment may also include surgery if there is significant damage to muscles or other organs.
Some of the major players in the polymyositis treatment market are Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, Genentech, Inc..
The polymyositis treatment market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Polymyositis Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Polymyositis Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Polymyositis Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Polymyositis Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Polymyositis Treatment Market Size & Forecast, 2018-2028 4.5.1 Polymyositis Treatment Market Size and Y-o-Y Growth 4.5.2 Polymyositis Treatment Market Absolute $ Opportunity
Chapter 5 Global Polymyositis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Polymyositis Treatment Market Size Forecast by Type
5.2.1 Immunosuppressant
5.2.2 Alkylating Agent
5.2.3 Immunoglobulin
5.2.4 Monoclonal Antibodies
5.2.5 Corticosteroids
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Polymyositis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Polymyositis Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Polymyositis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Polymyositis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Polymyositis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Polymyositis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Polymyositis Treatment Market Size Forecast by Type
9.6.1 Immunosuppressant
9.6.2 Alkylating Agent
9.6.3 Immunoglobulin
9.6.4 Monoclonal Antibodies
9.6.5 Corticosteroids
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Polymyositis Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Polymyositis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Polymyositis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Polymyositis Treatment Market Size Forecast by Type
10.6.1 Immunosuppressant
10.6.2 Alkylating Agent
10.6.3 Immunoglobulin
10.6.4 Monoclonal Antibodies
10.6.5 Corticosteroids
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Polymyositis Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Polymyositis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Polymyositis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Polymyositis Treatment Market Size Forecast by Type
11.6.1 Immunosuppressant
11.6.2 Alkylating Agent
11.6.3 Immunoglobulin
11.6.4 Monoclonal Antibodies
11.6.5 Corticosteroids
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Polymyositis Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Polymyositis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Polymyositis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Polymyositis Treatment Market Size Forecast by Type
12.6.1 Immunosuppressant
12.6.2 Alkylating Agent
12.6.3 Immunoglobulin
12.6.4 Monoclonal Antibodies
12.6.5 Corticosteroids
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Polymyositis Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Polymyositis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Polymyositis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Polymyositis Treatment Market Size Forecast by Type
13.6.1 Immunosuppressant
13.6.2 Alkylating Agent
13.6.3 Immunoglobulin
13.6.4 Monoclonal Antibodies
13.6.5 Corticosteroids
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Polymyositis Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Polymyositis Treatment Market: Competitive Dashboard
14.2 Global Polymyositis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hospira, Inc.
14.3.2 Antares Pharma, Inc.
14.3.3 Medexus Pharma, Inc.
14.3.4 Fresenius SE & Co. KGaA
14.3.5 Mylan N.V.
14.3.6 Alcami Corporation
14.3.7 Teva Pharmaceuticals
14.3.8 Novartis AG
14.3.9 Genentech, Inc.